Categories AlphaGraphs, Earnings, Technology
BOX Infographic: Highlights of Box’s Q1 2024 earnings report
Box, Inc. (NYSE: BOX), a leading content cloud platform, reported an increase in revenues and adjusted profit for the first quarter of 2024.
The company’s revenues increased 6% year-over-year to $251.9 million in the first three months of fiscal 2024. Remaining performance obligations, a measure of revenues to be realized in the next twelve months, rose sharply to $1.18 billion.
Reflecting the top-line growth, adjusted earnings moved up to $0.32 per share during the three-month period from $0.23 per share a year earlier. Unadjusted profit was $3.66 million or $0.02 per share, compared to a loss of $8.92 million or $0.06 per share in the prior-year quarter.
“In FY24, our pace of innovation continues to accelerate as we delivered on key roadmap milestones such as the general availability of Box Canvas and the next generation of Box Shuttle,” said Box’s CEO Aaron Levie.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
